AMLX · Amylyx Pharmaceuticals, Inc.
$28.96
+1.63 (+5.96%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$3.22B
Shares
111.42M
Volume · Oct 20
1.1M
Avg daily vol (3M)
2.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$27.33
Open$26.48
Day$26.27–27.35
52W close$11.38–39.66
Avg vol 30d1.4M
Short int12.7M · 11.4% float · 9.2d
Short vol35%
Last earningsAug 6, 2026
DataJan 2022–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 4, 2026
Est · unconfirmed
· in 2 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$152.09M
Trailing 12 months
Revenue growth YoY
-100.0%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$250.76M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+24.7%
Year over year · more shares
Price change (1Y)
+82.8%
Trailing year
Short interest
11.4%
Latest settlement · 9.2 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Amylyx reported Q2 2026 results with the last LUCIDITY Phase 3 participant completing their final visit, keeping the avexitide topline readout on track for late August or early September 2026, and maintained cash runway guidance into 2028 to support a potential 2027 commercial launch.
Bullish
- + Commercial and NDA readiness advancing with activated disease-state education campaign, expanded field medical affairs, and EAP initiation.
- + Q2 R&D expenses declined to $23.8M from $27.2M year-over-year.
Bearish
- − SG&A expenses rose to $21.9M from $15.6M year-over-year on a one-time legal charge and commercial build-out.
- − Q2 net loss widened to $43.4M ($0.39/share) from $41.4M ($0.46/share) a year ago.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 18.4 · elevated
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+41%
above
Price vs 50-day avg
−11%
below
RSI (14)
42
neutral
MACD trend
Negative
52-week position
56%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−16%
trailing
6-month return
+68%
trailing
YTD return
+126%
this year
Relative strength
+60%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $31 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
13 of 207 funds reported for Sep 30 · net +39.0K sh shares · +4 new
Insider flow
Distributing
Net -$2.9M over 90 days · 100% sells
Short interest
Falling
11.37% of float · ▼ -6.3% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
207 holders — near 3-yr high, broad support
Squeeze score
60
elevated · 0–100
Fundamentals
Revenue growth
+1613%
Y/Y
EPS growth
+65%
Y/Y
Free cash flow
$-123.5M
Balance sheet
$226.7M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−34%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+41%
Bullish
Price vs 50-day avg
−11%
Bearish
RSI (14)
42
Neutral
MACD trend
Negative
Bearish
52-week position
56%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $31 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
13 of 207 funds reported for Sep 30 · net +39.0K sh shares · +4 new
Insider flow
Distributing
Net -$2.9M over 90 days · 100% sells
Short interest
Falling
11.37% of float · ▼ -6.3% MoM · 9.2 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
207 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $11
Now $27 · 56%
Range high $40
vs 200-day avg +41%
vs 50-day avg -11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AMLX
this stock
Amylyx Pharmaceuticals, Inc.
|
$3.22B | +126.2% | +1612.9% | — | 11.4% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$62.65B | +25.8% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$48.90B | +1.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$48.14B | +32.4% | +4.3% | 67.7 | 2.6% |
|
HLN
Haleon plc
|
$44.59B | +0.3% | — | — | 0.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AMLX | -0.6% | -15.6% | +67.6% | -6.1% | +126.2% |
| SPY | -1.5% | -0.9% | +7.7% | +0.5% | +12.4% |
| vs SPY | +0.9% | -14.7% | +59.9% | -6.6% | +113.8% |
Key facts
CIK
1658551
CUSIP
03237H101
13F (30d)
13 filings
13 filers
Visit website
Investor relations